Alpha Tau price target raised to $12 from $9 at H.C. Wainwright

TipRanks

Thu, February 26, 2026 at 12:30 AM GMT+9 1 min read

In this article:

DRTS

+6.35%

H.C. Wainwright analyst Yi Chen raised the firm’s price target on Alpha Tau (DRTS) to $12 from $9 and keeps a Buy rating on the shares after Japan’s Ministry of Health, Labour and Welfare granted marketing approval for Alpha DaRT for the treatment of unresectable locally advanced or locally recurrent head and neck cancer. The approval in Japan further validates the Alpha DaRT platform and helps de-risk the clinical development in the U.S., the analyst tells investors.

Claim 50% Off TipRanks Premium

Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions

Stay ahead of the market with  the latest news and analysis  and maximize your portfolio's potential

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

**See Insiders’ Hot Stocks on TipRanks >> **

Read More on DRTS:

Disclaimer & DisclosureReport an Issue

Alpha Tau Wins First Overseas Approval as Japan Clears Alpha DaRT Cancer Therapy

Alpha Tau announces Japan’s MHLW granted marketing approbal for Alpha DaRT

Alpha Tau Outlines Aggressive 2026 Clinical Schedule and Manufacturing Ramp for Alpha DaRT Cancer Therapy

Alpha Tau issues letter to shareholders

Alpha Tau Medical Unveils Strong Pancreatic Cancer Alpha DaRT Data Ahead of ASCO GI 2026

Terms and Privacy Policy

Privacy Dashboard

More Info